Figure
1
Primary structure of thymalfasin.
Figure
2
Proposed mechanism of action of Zadaxin.
Figure
3
Serum woodchuck hepatitis virus (WHV) DNA in Zadaxin-treated
and placebotreated animals.
Figure
4
ZDX in combination with AMN and IFNα/β increases
survival of mice infected with influenza A virus.
Figure
5
Relapse time of B16 melanoma bearing mice treated with CY, IFN,
and ZDX.
Figure
6
Effect of increasing doses of Zadaxin on tumor reduction in
murine B16 melanoma.
Figure
7
Comparative adverse-event incidence.
Figure
8
Results at Chang Gung Memorial Hospital, Taiwan hepatitis B
trial at 18 months.
Figure
9
Time course of complete response in the Chang Gung Memorial
Hospital, Taiwan.
|
 |
Figure
10
Results from the Italian hepatitis B trial at 12 months.
Figure
11
Pooled intent-to-treat analysis of end-oftreatment biochemical
response.
Figure
12
Results in the US hepatitis C trial at 6 months.
Figure
13
Time to first ALT normalization in the US hepatitis C trial.
Figure
14
Results from the HIV trial in Italy at 12 months.
Figure
15
Clinical response to influenza vaccination.
Figure
16
Results from US influenza trial.
Figure
17
Antibody response to influenza vaccine with Zadaxin adjuvant
in hemodialysis patients.
Figure
18
Zadaxin+TACE: HCC survival.
Figure
19
Effect of Zadaxin on metastatic melanoma.
Figure
20
Serum Zadaxin concentrations after a single subcutaneous dose
(1.6 mg) of Zadaxin. |
